CAMP insider transactions
CAMP4 Therapeutics Corporation (CAMP) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
CAMP insiders
Everyone who has filed a Form 3, 4, 5 or 144 at CAMP4 Therapeutics Corporation, latest first. Follow anyone to get their next filing.
- Kelly GoldChief Financial Officer, since October 2024+$60.4K
- Andrew J. SchwabDirector, since October 2024+$10M-$2.5M
- Daniel TardiffChief Scientific Officer, since October 2025-$8,273
- 5AM Partners VI, LLC10% owner, since October 2024+$14.5M
- Richard A YoungDirector, since October 2024+$52K
- Yuri MaricichChief Medical Officer, since October 2024+$20.8K
- Josh Mandel-BrehmChief Executive Officer, Director, since October 2024+$20.8K
- Douglas E WilliamsDirector, since March 2025
- Steven H HoltzmanDirector, since October 2024
- Murray StewartDirector, since March 2025
- Amir NashatDirector, 10% owner, since October 2024+$12M
- Michael F MacLeanDirector, since April 2026
- Polaris Management Co. VII, L.L.C.10% owner, since October 2024+$22M
- Michael J HigginsDirector, since October 2024
- James P BoylanDirector, since October 2024
- Ravi I. ThadhaniDirector, since October 2024
- Paula RaganDirector, since October 2024
- David BumcrotChief Scientific Officer, since October 2024
- Polaris Partners GP X, L.L.C.10% owner, since October 2024
- Northpond Ventures II GP, LLC10% owner, since October 2024+$8.4M
- AH Equity Partners Bio I, L.L.C.10% owner, since October 2024+$8M
- Enavate Sciences GP, LLC10% owner, since October 2024+$15M
- Ingo ChakravartyDirector, since October 2024
- Jason CohenourDirector-$7,176
- Jill Kathleen FrizzleyDirector, since May 2024
- Jikun KimChief Financial Officer, since January 2023
- Christopher R. AdamsPresident and CEO, Director, since January 2024
- Richard M. ScottOfficer, since May 2022
- Brennen CarsonOfficer, since June 2022
- Jeffery R GardnerOfficer, Director+$541K
- Kirsten O. WolbergDirector
- Monica Van BerkelOfficer, since May 2022
- Jorge TitingerDirector
- Roxanne OulmanDirector
- Henry J MaierDirector
- Nathan LowstuterOfficer, since May 2022
- Wes CumminsDirector+$5.04M
- Jeffrey P. ClarkOfficer, since May 2022
- Scott ArnoldDirector
- Anand RauOfficer
Recent Form 3, 4, and 5 filings for CAMP
- Chief Financial Officer Gold Kelly bought $39,600 worth of shares (10,000 units at $3.96) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Schwab Andrew J. sold $1,616,000 worth of shares (400,000 units at $4.04) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Schwab Andrew J. sold $45 worth of shares (10 units at $4.50) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Schwab Andrew J. sold $879,719 worth of shares (191,865 units at $4.59) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Chief Scientific Officer Tardiff Daniel sold $8,273 worth of shares (1,738 units at $4.76), closing all direct ownership in the company (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Large owner 5am Partners Vi, Llc4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Schwab Andrew J.4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Young Richard A bought $27,024 worth of shares (16,378 units at $1.65), increasing direct ownership by 10% to 186,388 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Chief Medical Officer Maricich Yuri bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 108% to 12,611 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Chief Financial Officer Gold Kelly bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 10% to 74,428 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Chief Executive Officer Mandel-Brehm Josh bought $10,809 worth of shares (6,551 units at $1.65), increasing direct ownership by 2% to 284,968 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Young Richard A4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Schwab Andrew J.4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Williams Douglas E4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Holtzman Steven H4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Stewart Murray4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Nashat Amir4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Tardiff Daniel4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Maricich Yuri4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Gold Kelly4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Mandel-Brehm Josh4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Maclean Michael F4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 3 filed by new insider Maclean Michael F3 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Tardiff Daniel4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Maricich Yuri4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Gold Kelly4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Mandel-Brehm Josh4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 3 filed by new insider Tardiff Daniel3 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Schwab Andrew J. was granted 2,941,176 shares (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Large owner 5am Partners Vi, Llc bought $4,499,999 worth of shares (2,941,176 units at $1.53) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Large owner Polaris Management Co. Vii, L.L.C. bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Nashat Amir bought $1,999,999 worth of shares (1,307,189 units at $1.53) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Chief Medical Officer Maricich Yuri bought $9,999 worth of shares (6,060 units at $1.65) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Chief Financial Officer Gold Kelly bought $9,999 worth of shares (6,060 units at $1.65), increasing direct ownership by 10% to 67,877 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Chief Executive Officer Mandel-Brehm Josh bought $9,999 worth of shares (6,060 units at $1.65), increasing direct ownership by 2% to 278,417 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Young Richard A bought $24,999 worth of shares (15,151 units at $1.65), increasing direct ownership by 10% to 170,010 units (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Nashat Amir4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Young Richard A4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Holtzman Steven H4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Boylan James P4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Schwab Andrew J.4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Higgins Michael J4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Ragan Paula4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Thadhani Ravi I.4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Scientific Officer Bumcrot David4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Medical Officer Maricich Yuri4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Gold Kelly4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Chief Executive Officer Mandel-Brehm Josh4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Williams Douglas E4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 4 filed by Director Stewart Murray4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 3 filed by new insider Williams Douglas E3 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- SEC Form 3 filed by new insider Stewart Murray3 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Amendment: New insider Polaris Partners Gp X, L.L.C. claimed ownership of 909,090 shares (SEC Form 3)3/A - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Large owner Northpond Ventures Ii Gp, Llc converted options into 1,474,608 shares and bought $8,399,996 worth of shares (763,636 units at $11.00) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Large owner Ah Equity Partners Bio I, L.L.C. converted options into 1,398,067 shares and bought $7,999,992 worth of shares (727,272 units at $11.00) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Large owner Enavate Sciences Gp, Llc converted options into 2,422,166 shares and bought $14,999,996 worth of shares (1,363,636 units at $11.00) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Large owner 5am Partners Vi, Llc converted options into 2,018,825 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)
- Director Nashat Amir bought $9,999,990 worth of shares (909,090 units at $11.00) and converted options into 1,715,972 shares (SEC Form 4)4 - Camp4 Therapeutics Corp (0001736730) (Issuer)